The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Adriamycin     (7S,9R)-7-[(2S,4S,5S,6S)-4- amino-5-hydroxy...

Synonyms: Caelyx, Myocet, Adriblastin, Doxil, Rubex, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Adriablastin


Psychiatry related information on Adriablastin


High impact information on Adriablastin


Chemical compound and disease context of Adriablastin


Biological context of Adriablastin


Anatomical context of Adriablastin


Associations of Adriablastin with other chemical compounds


Gene context of Adriablastin


Analytical, diagnostic and therapeutic context of Adriablastin


  1. Primary chemotherapy in surgically resectable breast cancer. Bonadonna, G., Valagussa, P., Zucali, R., Salvadori, B. CA: a cancer journal for clinicians. (1995) [Pubmed]
  2. Doxorubicin-induced cardiac toxicity. Doroshow, J.H. N. Engl. J. Med. (1991) [Pubmed]
  3. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. Felker, G.M., Thompson, R.E., Hare, J.M., Hruban, R.H., Clemetson, D.E., Howard, D.L., Baughman, K.L., Kasper, E.K. N. Engl. J. Med. (2000) [Pubmed]
  4. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. Alexander, J., Dainiak, N., Berger, H.J., Goldman, L., Johnstone, D., Reduto, L., Duffy, T., Schwartz, P., Gottschalk, A., Zaret, B.L. N. Engl. J. Med. (1979) [Pubmed]
  5. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. Gabrilove, J.L., Jakubowski, A., Scher, H., Sternberg, C., Wong, G., Grous, J., Yagoda, A., Fain, K., Moore, M.A., Clarkson, B. N. Engl. J. Med. (1988) [Pubmed]
  6. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Otterson, G.A., Villalona-Calero, M.A., Sharma, S., Kris, M.G., Imondi, A., Gerber, M., White, D.A., Ratain, M.J., Schiller, J.H., Sandler, A., Kraut, M., Mani, S., Murren, J.R. Clin. Cancer Res. (2007) [Pubmed]
  7. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. Kim, K.I., Kang, J.H., Chung, J.K., Lee, Y.J., Jeong, J.M., Lee, D.S., Lee, M.C. J. Nucl. Med. (2007) [Pubmed]
  8. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Ottewell, P.D., Deux, B., Mönkkönen, H., Cross, S., Coleman, R.E., Clezardin, P., Holen, I. Clin. Cancer Res. (2008) [Pubmed]
  9. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Ravel, D., Dubois, V., Quinonero, J., Meyer-Losic, F., Delord, J., Rochaix, P., Nicolazzi, C., Ribes, F., Mazerolles, C., Assouly, E., Vialatte, K., Hor, I., Kearsey, J., Trouet, A. Clin. Cancer Res. (2008) [Pubmed]
  10. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Li, Q.Q., Xu, J.D., Wang, W.J., Cao, X.X., Chen, Q., Tang, F., Chen, Z.Q., Liu, X.P., Xu, Z.D. Clin. Cancer Res. (2009) [Pubmed]
  11. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. Mitsiades, N., Poulaki, V., Leone, A., Tsokos, M. J. Natl. Cancer Inst. (1999) [Pubmed]
  12. Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Kurabayashi, M., Dutta, S., Jeyaseelan, R., Kedes, L. Mol. Cell. Biol. (1995) [Pubmed]
  13. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. Alderton, P., Gross, J., Green, M.D. Cancer Res. (1990) [Pubmed]
  14. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study. Khoo, K., Brandes, L., Reyno, L., Arnold, A., Dent, S., Vandenberg, T., Lebwohl, D., Fisher, B., Eisenhauer, E. J. Clin. Oncol. (1999) [Pubmed]
  15. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Freter, C.E., Lee, T.C., Billingham, M.E., Chak, L., Bristow, M.R. Am. J. Med. (1986) [Pubmed]
  16. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. Lipshultz, S.E., Lipsitz, S.R., Mone, S.M., Goorin, A.M., Sallan, S.E., Sanders, S.P., Orav, E.J., Gelber, R.D., Colan, S.D. N. Engl. J. Med. (1995) [Pubmed]
  17. More on skin cancer after the extravasation of doxorubicin. Silverman, H.I. N. Engl. J. Med. (1995) [Pubmed]
  18. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. Wood, W.C., Budman, D.R., Korzun, A.H., Cooper, M.R., Younger, J., Hart, R.D., Moore, A., Ellerton, J.A., Norton, L., Ferree, C.R. N. Engl. J. Med. (1994) [Pubmed]
  19. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. Muss, H.B., Thor, A.D., Berry, D.A., Kute, T., Liu, E.T., Koerner, F., Cirrincione, C.T., Budman, D.R., Wood, W.C., Barcos, M. N. Engl. J. Med. (1994) [Pubmed]
  20. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. Muss, H.B., Case, L.D., Richards, F., White, D.R., Cooper, M.R., Cruz, J.M., Powell, B.L., Spurr, C.L., Capizzi, R.L. N. Engl. J. Med. (1991) [Pubmed]
  21. Possible prevention of adriamycin-induced alopecia by tocopherol. Wood, L.A. N. Engl. J. Med. (1985) [Pubmed]
  22. Protection from chemotherapy-induced alopecia in a rat model. Hussein, A.M., Jimenez, J.J., McCall, C.A., Yunis, A.A. Science (1990) [Pubmed]
  23. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Rogan, A.M., Hamilton, T.C., Young, R.C., Klecker, R.W., Ozols, R.F. Science (1984) [Pubmed]
  24. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Arap, W., Pasqualini, R., Ruoslahti, E. Science (1998) [Pubmed]
  25. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E. Cell (1993) [Pubmed]
  26. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Perez, G.I., Knudson, C.M., Leykin, L., Korsmeyer, S.J., Tilly, J.L. Nat. Med. (1997) [Pubmed]
  27. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Friesen, C., Herr, I., Krammer, P.H., Debatin, K.M. Nat. Med. (1996) [Pubmed]
  28. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. DeFeo-Jones, D., Garsky, V.M., Wong, B.K., Feng, D.M., Bolyar, T., Haskell, K., Kiefer, D.M., Leander, K., McAvoy, E., Lumma, P., Wai, J., Senderak, E.T., Motzel, S.L., Keenan, K., Van Zwieten, M., Lin, J.H., Freidinger, R., Huff, J., Oliff, A., Jones, R.E. Nat. Med. (2000) [Pubmed]
  29. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. Lipshultz, S.E., Colan, S.D., Gelber, R.D., Perez-Atayde, A.R., Sallan, S.E., Sanders, S.P. N. Engl. J. Med. (1991) [Pubmed]
  30. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. Clavell, L.A., Gelber, R.D., Cohen, H.J., Hitchcock-Bryan, S., Cassady, J.R., Tarbell, N.J., Blattner, S.R., Tantravahi, R., Leavitt, P., Sallan, S.E. N. Engl. J. Med. (1986) [Pubmed]
  31. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. Moertel, C.G., Lefkopoulo, M., Lipsitz, S., Hahn, R.G., Klaassen, D. N. Engl. J. Med. (1992) [Pubmed]
  32. Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Roninson, I.B., Abelson, H.T., Housman, D.E., Howell, N., Varshavsky, A. Nature (1984) [Pubmed]
  33. Molecular portraits of human breast tumours. Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., Lønning, P.E., Børresen-Dale, A.L., Brown, P.O., Botstein, D. Nature (2000) [Pubmed]
  34. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. Speyer, J.L., Green, M.D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A. N. Engl. J. Med. (1988) [Pubmed]
  35. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Kramer, R.A., Zakher, J., Kim, G. Science (1988) [Pubmed]
  36. Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. Grzegorzewski, K., Ruscetti, F.W., Usui, N., Damia, G., Longo, D.L., Carlino, J.A., Keller, J.R., Wiltrout, R.H. J. Exp. Med. (1994) [Pubmed]
  37. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. Logothetis, C.J., Dexeus, F.H., Sella, A., Amato, R.J., Kilbourn, R.G., Finn, L., Gutterman, J.U. J. Natl. Cancer Inst. (1990) [Pubmed]
  38. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Lyu, Y.L., Kerrigan, J.E., Lin, C.P., Azarova, A.M., Tsai, Y.C., Ban, Y., Liu, L.F. Cancer Res. (2007) [Pubmed]
  39. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. Piguet, A.C., Semela, D., Keogh, A., Wilkens, L., Stroka, D., Stoupis, C., St-Pierre, M.V., Dufour, J.F. J. Hepatol. (2008) [Pubmed]
  40. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Blay, J.Y., von Mehren, M., Samuels, B.L., Fanucchi, M.P., Ray-Coquard, I., Buckley, B., Gilles, L., Lebedinsky, C., Elsayed, Y.A., Le Cesne, A. Clin. Cancer Res. (2008) [Pubmed]
  41. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. Kitazono, M., Sumizawa, T., Takebayashi, Y., Chen, Z.S., Furukawa, T., Nagayama, S., Tani, A., Takao, S., Aikou, T., Akiyama, S. J. Natl. Cancer Inst. (1999) [Pubmed]
  42. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W.H., Mendelsohn, J. J. Natl. Cancer Inst. (1993) [Pubmed]
  43. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. Yen, H.C., Oberley, T.D., Vichitbandha, S., Ho, Y.S., St Clair, D.K. J. Clin. Invest. (1996) [Pubmed]
  44. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. Herr, I., Wilhelm, D., Böhler, T., Angel, P., Debatin, K.M. EMBO J. (1997) [Pubmed]
  45. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Zhu, S., Waguespack, M., Barker, S.A., Li, S. Clin. Cancer Res. (2007) [Pubmed]
  46. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. Smalley, R.V., Andersen, J.W., Hawkins, M.J., Bhide, V., O'Connell, M.J., Oken, M.M., Borden, E.C. N. Engl. J. Med. (1992) [Pubmed]
  47. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. Foon, K.A., Sherwin, S.A., Abrams, P.G., Longo, D.L., Fer, M.F., Stevenson, H.C., Ochs, J.J., Bottino, G.C., Schoenberger, C.S., Zeffren, J. N. Engl. J. Med. (1984) [Pubmed]
  48. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P. N. Engl. J. Med. (1993) [Pubmed]
  49. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. Lamm, D.L., Blumenstein, B.A., Crawford, E.D., Montie, J.E., Scardino, P., Grossman, H.B., Stanisic, T.H., Smith, J.A., Sullivan, J., Sarosdy, M.F. N. Engl. J. Med. (1991) [Pubmed]
WikiGenes - Universities